On June 30, 2025, the Federal Circuit issued a precedential decision in Eye Therapies, LLC v. Slayback Pharma, LLC, reversing the Patent Trial and Appeal Board’s (PTAB’s) claim construction of the phrase “consisting...more
7/10/2025
/ Appeals ,
CAFC ,
Claim Construction ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Obviousness ,
Patent Examinations ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent Validity ,
Pharmaceutical Patents ,
Prior Art ,
Reversal
Knowing what qualifies as prior art is a core requirement of patent practitioners—whether in life sciences, in the technology sectors or in post-grant proceedings. It is important to keep abreast of changes to the rules,...more